ClinicalTrials.gg
WithdrawnNCT02563782PORTRAYUpdated Jul 26, 2017

Study to Evaluate Sub-retinal Transplantation of Retinal Pigmented Epithelial Cells in Patients With Dry AMD

A Phase 2 interventional study of Sub-retinal transplantation of MA09-hRPE cells and tacrolimus and mycophenolate mofetil in Age-Related Macular Degeneration, sponsored by Astellas Institute for Regenerative Medicine. Withdrawn at 1 site in United States. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2017-07-26.

Sponsored by Astellas Institute for Regenerative Medicine (part of Astellas Pharma Inc) · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Changes to the study design and the cell line

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Macular Degeneration by Astellas Pharma Inc — 3 open to participants now, 5 under way, none of them phase 3. Macular Degeneration · Astellas Pharma Inc.

Enrollment
19th of 19
0 · median 63
Started
2015
the only one that year
Phase 2
6 of 23
none open now
Registered
13th of 23
by date

Among the 23 studies in Macular Degeneration by Astellas Pharma Inc, this one is the 19th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2015, is one of 6 in phase 2, and was the 13th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

3 of the 23 studies in Macular Degeneration by Astellas Pharma Inc are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Macular Degeneration by Astellas Pharma Inc, or all of them as a file.
02

Study summary

To evaluate the safety of 3 regimens of short-term, low-dose systemic IMT as rejection prophylaxis prior to and/or following transplant of MA09-hRPE cells.

Read the detailed description

This study will be a Phase 2, double-masked, randomized, parallel group, sham surgery/placebo control, multi-center trial. Subjects will be randomized in a 3:1 ratio to either the treatment or control group respectively. Subjects randomized to the treatment group will receive transplantation with 200,000 MA09-hRPE (human embryonic stem cell derived retinal pigmented epithelial)cells in one eye. Subjects randomized to the control group will have a sham surgery without transplantation of MA09-hRPE cells. The study eye must meet all eligibility criteria. If both eyes meet all eligibility criteria, then the study eye will be the eye with the worst Best Corrected Visual Acuity (BCVA) score at screening. If both eyes have identical BCVA scores, then the study eye will be chosen by the Investigator and the subject. There will be 3 cohorts, each with a different regimen of low-dose IMT [tacrolimus and mycophenolate mofetil (MMF)]. Subjects will be randomized to treatment or control within cohorts, defined by severity of BCVA in the study eye at Screening. Enrollment in Cohort 1 and 2 will be concurrent. Enrollment into Cohort 3 will begin once Cohort 2 is fully enrolled.

03

Conditions studied

  • Age-Related Macular Degeneration
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Geographic atrophy (GA) secondary to AMD with no evidence of prior to active choroidal neovascularization (CNV) in the study eye.
  • BCVA in the study eye must be between 4 and 58 Early Treatment of Diabetic Retinopathy Study (EDTRS) letters (20/800 to 20/80; 0.025-0.25)
  • Subjects must be willing to take IMT and willing to discontinue any medication that has a known strong interaction with tacrolimus or mycophenolate mofetil (MMF)

Exclusion criteria

Exclusion Criteria:

  • Macular atrophy due to causes other than AMD
  • Other sight-threatening ocular disease
  • Current or prior history of optic neuropathy, retinal dystrophy, retinitis pigmentosa, chorioretinitis, vasoocclusive disease, retinal vascular disease or retinal degenerative disease OTHER than AMD
  • History of uveitis
  • History of allergic reaction to sulfa drugs
  • Solid organ or bone marrow transplant recipient
  • History of within the previous 5 years (except for BCC (basal cell carcinoma), SCC (squamous cell carcinoma) or in-situ cervical)
  • History of myocardial infarction with past 12 months
  • History of cardiac dysrhythmia
  • History of diabetes mellitus, bowel disease, tuberculosis
  • Prior treatment for non-exudative AMD
  • Intraocular, refractive or cataract surgery in the last 12 weeks
  • Prior retinal surgery, vitrectomy, macular laser photocoagulation, external beam radiation therapy, transpupillary thermotherapy, glaucoma filtration surgery or corneal surgery (except cataract surgery)
  • Receipt of gene transfer of cell transplant therapy in a prior clinical trial
  • Participation in any other interventional clinical trial within the last 12 weeks
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Sham comparator
    Control group

    Sham surgery and placebo immunosuppressive therapy (IMT)

    Drug: Placebo tacrolimus and mycophenolate mofetil · Procedure: Sham Surgery

  • Active comparator
    Active Group

    Sub-retinal transplantation of MA09-hRPE cells and IMT

    Biological: Sub-retinal transplantation of MA09-hRPE cells · Drug: tacrolimus and mycophenolate mofetil

Interventions

  • BiologicalSub-retinal transplantation of MA09-hRPE cells

    transplantation

  • Drugtacrolimus and mycophenolate mofetil

    Drug pages: Tacrolimus · Mycophenolic Acid

    Immunosuppressive Agents

  • DrugPlacebo tacrolimus and mycophenolate mofetil

    placebo

  • ProcedureSham Surgery

    Sham surgery

06

What researchers measure

Primary outcomes

  1. Number of subjects with evidence of graft failure or rejection.

    Time frame: 18 months

Secondary outcomes

  1. Change in area of geographic atrophy by Optical coherence tomography

    Change from baseline to Week 78

    Time frame: 18 months

  2. Change in area of geographic atrophy by Autofluorescence

    Change from baseline to Week 78

    Time frame: 18 months

  3. Change in average Best Corrected Visual Acuity (BCVA)

    Change from baseline to Week 78

    Time frame: 18 months

07

Study locations

1 site
  • Wills Eye Institute
    Philadelphia, Pennsylvania 19107, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2015 to primary completion in May 2017, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2015
First posted
Sep 30, 2015
StartActual
Aug 24, 2015
Primary completionActual
May 5, 2017
CompletionActual
May 5, 2017
Last update
Jul 26, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02563782
Responsible party
Sponsor
First posted
Sep 30, 2015
Start date
Aug 24, 2015
Primary completion
May 5, 2017
Completion
May 5, 2017
Last update
Jul 26, 2017

Study contacts

Medical Director
study director · Astellas Institute for Regenerative Medicine

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tacrolimus · Mycophenolic Acid

Start the discussion